Kilsdonk E P, Morel D W, Johnson W J, Rothblat G H
Department of Biochemistry, Medical College of Pennsylvania, Philadelphia 19129, USA.
J Lipid Res. 1995 Mar;36(3):505-16.
The effect of oxysterols on efflux of cholesterol from mouse L-cell fibroblasts, rat Fu5AH hepatoma cells, J774 macrophages, and human EA.hy 926 endothelial cells was studied. Cells were preincubated with 25-hydroxycholesterol (25-OHC) either during labeling of the cells with [3H]cholesterol or during equilibration after labeling. Subsequently, the release of [3H]cholesterol into medium containing 0.2 mg HDL3/ml was measured and the fractional release of cellular [3H]cholesterol was calculated. Pretreatment with 25-OHC (1 microgram/ml) caused a 30% reduction in [3H]cholesterol efflux from L-cells during 8 h of incubation with HDL3. 25-OHC also inhibited cholesterol efflux from Fu5AH and J774 cells, but the effect was less marked. There was only a small, nonsignificant reduction of efflux from EA.hy 926 cells. The mechanisms of 25-OHC-induced inhibition of cellular cholesterol efflux was further studied in L-cells, because of their sensitivity to 25-OHC treatment. The effect of 25-OHC on cholesterol efflux was dose-dependent, with significant effects seen at 25-OHC concentrations as low as 50 ng/ml. The half-time for cholesterol efflux from 25-OHC-treated cells (5 micrograms/ml) was 13.0 +/- 3.3 h compared to 5.7 +/- 1.0 in control cells, corresponding to a 55% reduction in the rate of cholesterol release. Other oxysterols, including 7-ketocholesterol, 7 alpha- and 7 beta-hydroxycholesterol, and 22(S)-hydroxycholesterol also inhibited [3H]cholesterol efflux from L-cells significantly, but to a lesser degree. 25-Hydroxycholesterol (5 micrograms/ml) reduced efflux from both normal and cholesterol-enriched cells by 31 and 14%, respectively. Inhibition of efflux was similar when reconstituted HDL3-apolipoprotein/phosphatidylcholine particles or small unilamellar phosphatidylcholine vesicles were used as cholesterol acceptors instead of HDL3. The content of phospholipids, cholesterol and the FC/PL ratio of intact cells and from isolated plasma membrane vesicles were the same for control and 25-OHC-treated cells. Efflux of [3H]cholesterol from plasma membranes isolated from 25-OHC-treated cells was 20% less than efflux from membranes from control cells. The difference in efflux observed in intact cells is partially explained by the reduction in efflux from the plasma membrane. In conclusion, our studies suggest that oxysterols, especially 25-hydroxycholesterol, can reduce cellular cholesterol efflux in vitro. Therefore oxysterols, either endogenous or derived from the diet, may influence cellular cholesterol efflux in vivo, the first step in reverse cholesterol transport.
研究了氧化甾醇对小鼠L细胞成纤维细胞、大鼠Fu5AH肝癌细胞、J774巨噬细胞和人EA.hy 926内皮细胞中胆固醇流出的影响。在用[3H]胆固醇标记细胞期间或标记后平衡期间,将细胞与25-羟基胆固醇(25-OHC)预孵育。随后,测量[3H]胆固醇向含有0.2mg HDL3/ml的培养基中的释放,并计算细胞[3H]胆固醇的分数释放。用25-OHC(1μg/ml)预处理导致在与HDL3孵育8小时期间,L细胞中[3H]胆固醇流出减少30%。25-OHC也抑制Fu5AH和J774细胞中的胆固醇流出,但效果不太明显。EA.hy 926细胞的流出仅略有减少且无统计学意义。由于L细胞对25-OHC处理敏感,因此在L细胞中进一步研究了25-OHC诱导的细胞胆固醇流出抑制机制。25-OHC对胆固醇流出的影响呈剂量依赖性,在低至50ng/ml的25-OHC浓度下即可观察到显著效果。来自25-OHC处理细胞(5μg/ml)的胆固醇流出半衰期为13.0±3.3小时,而对照细胞为5.7±1.0小时,相当于胆固醇释放速率降低55%。其他氧化甾醇,包括7-酮胆固醇、7α-和7β-羟基胆固醇以及22(S)-羟基胆固醇也显著抑制L细胞中[3H]胆固醇流出,但程度较小。25-羟基胆固醇(5μg/ml)分别使正常细胞和富含胆固醇的细胞中的流出减少31%和14%。当用重组HDL3-载脂蛋白/磷脂酰胆碱颗粒或小单层磷脂酰胆碱囊泡代替HDL3作为胆固醇受体时,流出抑制情况相似。对照细胞和25-OHC处理细胞的完整细胞以及分离的质膜囊泡中的磷脂、胆固醇含量和FC/PL比值相同。从25-OHC处理细胞分离的质膜中[3H]胆固醇的流出比对照细胞的膜流出少20%。在完整细胞中观察到的流出差异部分可由质膜流出减少来解释。总之,我们的研究表明氧化甾醇,尤其是25-羟基胆固醇,可在体外降低细胞胆固醇流出。因此,内源性或饮食来源的氧化甾醇可能会影响体内细胞胆固醇流出,这是逆向胆固醇转运的第一步。